ACCESS Newswire
30 Nov 2021, 03:01 GMT+10
GENEVA, SWITZERLAND / ACCESSWIRE / November 29, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ('Relief'), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc. (NRXP) ('NRx'), has announced it completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with aviptadil in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. According to the press release, the analysis, conducted by Prof. David Schoenfeld, who they report is one of the world's most widely published statisticians with unique expertise in life-threatening diseases of the lung, examined the subgroup of patients in the COVID-AIV trial (NCT 04311697) that remained in respiratory failure despite treatment with remdesivir. The press release also reported that the analysis identified a statistically significant (P=.03) 2.5-fold increased odds of being alive and free of respiratory failure at 60 days (the primary endpoint) and a statistically significant (P=.006) four-fold higher odds of being alive at day 60 among patients treated with aviptadil compared to those treated with placebo. The related NRx press release can be accessed through the following link.
ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100(TM) (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed and development-stage programs.
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
[email protected]
FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether aviptadil will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with COVID-19, and (ii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holdings AG
Get a daily dose of Pittsburgh Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Pittsburgh Star.
More InformationWASHINGTON, 7th June, 2025 (WAM) -- The United States recorded 122 new measles cases this week, with only four reported in Texas. Health...
WASHINGTON, 27th May, 2025 (WAM) -- Two people were killed and nine others, including three teenagers, injured in a shooting at Philadelphia's...
Protesters attend the 'No Kings' rally in San Diego, California, U.S., June 14, 2025, /VCG About 2,000 protests against the Trump...
US President Donald Trump is set to preside over a military parade at Washington, DC's Lincoln Memorial on his 79th birthday Saturday,...
The 49ers committed to QB Brock Purdy with a huge new deal but will be making transitions at quite a few positions after being forced...
Tommy Yarrish FRISCO, TexasWith the offseason program in the rear-view mirror, training camp is the last thing standing in front...
BEIJING, China: Chinese civil servants are now facing stricter rules on dining together, with some local authorities limiting group...
DUBAI, U.A.E.: As violence escalates between Iran and Israel, Tehran is turning to its Gulf neighbors to help broker a ceasefire —...
LONDON, U.K.: On June 15, Britain named Blaise Metreweli as the first woman to lead the Secret Intelligence Service, commonly known...
BARCELONA/MADRID, Spain: With another record-breaking tourist season underway, thousands of residents across southern Europe marched...
NEW DELHI, India: The flight data recorder from the crashed Air India plane was found on June 13. This vital discovery may help investigators...
BEIJING, China: A typhoon altered its course and struck Hainan Island, southern China, late on the night of June 13. Typhoon Wutip...